Ignite Creation Date:
2024-05-06 @ 8:19 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06334575
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-03-28
First Post:
2024-03-21
Brief Title:
Molecular Signatures Associated With Response to ICS Treatment in Patients With COPD Stratified by Eosinophil Levels
Sponsor:
Maria Joyera Rodríguez
Organization:
Fundacion Clinic per a la Recerca Biomédica
Study Overview
Official Title:
Molecular Signatures Associated With Response to ICS Treatment in Patients With COPD Stratified by Eosinophil Levels
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
3TR-ICS-COPD
Brief Summary:
The 3TR-ICS COPD study is an international multicentre randomized parallel controlled study that will recruit clinically stable former smokers COPD patients with no exacerbations in the previous 8 weeks on treatment with dual long-acting bronchodilators LABALAMA minimum 8 weeks of usage not receiving ICS either naïve or 3 months since last usage The overall objective of this clinical trial is to identify the molecular signatures associated with the molecular response to ICS treatment in patients with COPD stratified by the levels of circulating eosinophils and the potential influence of the pulmonary microbiome
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None